Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Pulmonology
Alpha1-Antitrypsin Deficiency
Last Updated: February 14, 2002
Synonyms and
related keywords:
alpha-1 antiprotease
deficiency, alpha1
antiprotease
deficiency, alpha-1
antitrypsin deficiency,
AAT Rate this Article
Email to a Colleague
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Author: Paul Fairman, MD, Medical Director of Lung Transplant Service, Professor,
Department of Internal Medicine, Divisions of Pulmonary and Critical Care Medicine,
Medical College of Virginia
Paul Fairman, MD, is a member of the following medical societies: American College
of Chest Physicians, American College of Physicians, American Physiological Society,
American Thoracic Society, International Society for Heart and Lung Transplantation,
Society of Critical Care Medicine, and Southern Medical Association
Editor(s): Ryland P Byrd, Jr, MD, Chief of Pulmonary Medicine, Medical Director of
Respiratory Therapy, Quillen VA Medical Center, Associate Professor, Department of
Internal Medicine, Division of Pulmonary Medicine, Quillen College of Medicine;
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Om
Prakash Sharma, MD, Professor, Department of Medicine, Division of Pulmonary and
Critical Care Medicine, University of Southern California; Timothy D Rice, MD,
Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent
Medicine, St Louis University; and Zab Mohsenifar, MD, Director, Division of
Pulmonary/Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical
Center; Professor, Department of Internal Medicine, University of California at Los
Angeles School of Medicine
INTRODUCTION Section 2 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Frequency:
In the US: This genetic defect affects 1 per 3000-5000 individuals. AAT is 1 of the
3 most common lethal genetic diseases among whites. The other 2 common fatal
genetic defects are cystic fibrosis and Down syndrome.
Internationally: Similar rates are found among whites worldwide.
Mortality/Morbidity: Specific morbidity and mortality rates are unknown. Not all patients
with homozygous deficiency develop symptomatic emphysema or cirrhosis; however,
among those who develop symptomatic disease, the mortality rate is very high.
Age: The enzyme deficiency is present from birth and can be an unusual cause of
neonatal jaundice. Symptomatic emphysema develops in the fourth decade of life in
smokers and a decade later in nonsmokers.
CLINICAL Section 3 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
History: Symptoms of AAT deficiency emphysema are limited to the respiratory system.
If recurrent episodes of cough are most prominent, patients may be treated with
multiple courses of antibiotics and evaluated for sinusitis, postnasal drip, or
gastroesophageal reflux.
Causes: The name of this disease originated from a deficiency of the serum
antiprotease, originally called AAT. The responsible genetic defect affects 1 in 3000-
5000 individuals, making it 1 of the 3 most common lethal genetic diseases among
whites. The other 2 common fatal genetic defects are cystic fibrosis and Down
syndrome. Fortunately, not every individual with AAT deficiency develops clinically
significant disease.
DIFFERENTIALS Section 4 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Bronchiectasis
Bronchitis
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease
Emphysema
Kartagener Syndrome
Other Problems to be Considered:
WORKUP Section 5 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Lab Studies:
o Clinical features that suggest the possibility of AAT deficiency and the need
for serum testing include emphysema at an early age, emphysema in a
nonsmoker (or light smoker), a family history of emphysema, emphysema of
the lower lungs (as determined by chest radiograph), adult-onset asthma,
and recurrent bronchitis.
Phenotyping
o Test patients with low or borderline serum levels with phenotyping. Use an
experienced reference laboratory for this test. Free genetic screening kits
are available through Bayer Laboratories at 800-288-8371, and samples can
be processed for free at the AAT Deficiency Detection Center, University of
Utah, 801-328-4662.
o More than 100 different phenotypic variants of AAT deficiency have been
identified, but 1 phenotype, PiZZ, is responsible for nearly all cases of AAT
emphysema and liver disease. PiZZ phenotype serum levels range from 3.4-
7 mol/L, about 10-20% of the reference range levels.
Evaluate hepatic function in patients with low or borderline levels of AAT. Measure
serum transaminases, bilirubin, albumin, and routine clotting function (activated
partial thromboplastin time and international normalized ratio).
Imaging Studies:
Chest radiograph
o The process is not uniform; certain areas are affected more than others.
o Affected regions also are described as oligemic because they lack the
normal rich pattern of branching blood vessels.
High-resolution CT scan
o Mild forms of AAT disease can be missed by HRCT scan, but, when the
disease is moderate, discerning the panlobular nature of the process and the
characteristic lower zone predominance is possible.
Other Tests:
Histologic Findings: All forms of emphysema destroy alveolar walls and leave
permanent abnormal enlargement of the airspace distal to the terminal bronchiole. In AAT
deficiency, the emphysematous areas are distributed uniformly throughout the acinus
(lobule) and, for reasons that are not known, primarily in the basilar portions of the lung.
This contrasts with centrilobular emphysema characteristic of cigarette smoking, which
predominantly affects the respiratory bronchioles in the central portion of the lobule,
usually initially at the apex of the lung.
TREATMENT Section 6 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Medical Care: Preventing or slowing the progression of lung disease is the major goal of
AAT deficiency management. Facilitate this goal by decreasing any proinflammatory
stimuli in the alveolus, including smoking, asthma, or respiratory infection. Alternatively,
augmenting or replacing the deficient enzyme, and thereby moderating inflammatory
stimuli, is possible. Most patients are identified only after they develop lung disease, and
the goals of treating AAT deficiency emphysema are similar to those for treating all forms
of emphysema.
Quitting smoking
o No treatment for emphysema has a greater effect on survival than quitting
smoking.
o Make a concerted effort to inform patients about the serious consequences
of smoking on AAT deficiency and provide them with one of the many aids to
help them quit.
o Remember the 4 stages in the process of helping patients become
nonsmokers—(1) ask about smoking habits; (2) advise about health effects;
(3) assist the patient with encouragement, education, and nicotine
replacement; and (4) arrange follow-up.
o Most patients with AAT deficiency quit successfully.
Pulmonary rehabilitation
o According to a National Institutes of Health (NIH) workshop, pulmonary
rehabilitation is defined as "a multi-disciplinary continuum of services
directed to persons with pulmonary disease and their families, usually by an
interdisciplinary team of specialists, with the goal of achieving and
maintaining the individual's maximum level of independence and function in
the community."
o Most programs combine education, exercise conditioning, breathing training,
chest physical therapy, and respiratory muscle training with nutritional
counseling and psychological support.
o Therapy does not improve pulmonary function test results, but well-
controlled studies documented significant improvement in exercise
endurance, exercise work capacity, level of dyspnea, quality of life, and
reducing health-related expenses.
Reducing hypoxemia
o Hypoxemia accelerates mortality in patients with severe airflow obstruction,
and oxygen supplementation prolongs survival for this group.
o Oxygen also increases exercise capacity, improves mental performance,
decreases dyspnea with exercise, and improves sleep quality.
o Stable patients with resting hypoxia benefit most if they wear their oxygen
mask continuously. The benefits for patients with hypoxemia only during
exercise or sleep are not as clear, and oxygen may be prescribed for those
intervals when the oxygen saturation is likely to be low.
Replacing enzymes
o AAT-deficient individuals who have or show signs of developing significant
emphysema can be treated with Prolastin, a pooled, purified, human plasma
protein concentrate replacement for the missing enzyme that has been
screened for HIV and hepatitis viruses. It also is heat-treated as an
additional precaution against transmission of infection. Immunize patients
against hepatitis regardless.
o Weekly intravenous infusions of Prolastin restore serum and alveolar AAT
concentrations to protective levels. Although other regimens for
administration have proven to provide similar serum levels, only the weekly
infusion schedule has US Food and Drug Administration approval.
o No controlled studies have proven that intravenous augmentation therapy
improves survival or slows the rate of emphysema progression. Results from
the NIH patient registry and a comparison of Danish and German registries
have been published, and both suggest that augmentation therapy has
beneficial effects. Although they were not controlled treatment trials, the
similarity of the results suggests that the findings are significant.
o The NIH report described an overall death rate 1.5 times higher for those
who did not receive augmentation therapy and a rate of FEV 1 decline (54
mL/y) in AAT-deficient individuals approximately twice that of healthy
nonsmokers but approximately 50% that of smokers (108 mL/y). Prolastin
treatment did not improve the average FEV1 decline (54 mL/y); however,
participants with moderate airflow obstruction (FEV 1 35-49% of predicted
value) experienced a slower rate of decline (mean difference 27 mL/y).
These findings bolster the long-held belief that augmentation therapy
provides clinical benefit. No firm guidelines have been developed for
initiating or continuing augmentation therapy.
o Most pulmonary physicians require the serum level to be below the threshold
protective value and that the patient have 1 or more of the following: signs of
significant lung disease such as chronic productive cough or unusual
frequency of lower respiratory infection, airflow obstruction, accelerated
decline of FEV1, or chest radiograph or CT scan evidence of emphysema.
o The American Thoracic Society recommends starting treatment when the
FEV1 is less than 80% of the patient's predicted value.
Surgical Care: Two surgical approaches may help selected patients with AAT deficiency.
o This procedure has generated nationwide interest and hope for patients with
all types of emphysema.
o Selected patients with severe emphysema and significant air trapping have
experienced symptomatic improvement by removing the most severely
affected 20-35% of each lung. Spirometry and exercise tolerance generally
improve following postoperative recovery. Dyspnea generally is diminished.
The effects on blood gas values are variable.
o Some of the enthusiasm for the procedure has waned, even as surgical
mortality rates have diminished, because the duration of improvement
seems to be brief; an accelerated rate of FEV1 decline appears to occur after
the surgery.
Lung transplantation
o Transplantation is the second surgical option for patients with severe AAT
emphysema.
o If patients are at substantial risk of early mortality and are otherwise healthy,
they may be candidates for lung transplantation.
o Contact a local transplant center before patients become too ill (cachexia,
inactivity, frequent infections). Unfortunately, the average waiting time for a
transplant in the United States is 18-24 months, and the uncertainties of
emphysema exacerbations and complications that might prevent
transplantation make it imperative that patients be referred well in advance
of need.
o Offer patients with an FEV1 less than 35% of predicted value (5-y mortality
rate of 50%), especially men or individuals with substantial broncho-
reactivity, the opportunity to discuss the option with a transplant physician.
Consultations: The diagnosis of AAT deficiency emphysema is not difficult, but most
physicians will have no experience treating a patient, providing counseling, or answering
the questions that an uncommon hereditary disorder generates. Several visits with a
specialist in the first year usually are enough to meet a patient's needs. The Alpha-1
National Association, 1-800-4ALPHA-1, http://www.alpha1.org/ can facilitate locating
physicians with interest and experience in caring for these patients.
Diet: Patients with advanced chronic obstructive lung disease are characterized by a
significant reduction in fat-free muscle mass. This pulmonary cachexia is common in
patients with AAT deficiency and is associated with a decline in clinical status. The
syndrome is a result of multiple factors, including hypermetabolism, drug therapy,
inactivity, and aging. Prolonged glucocorticoid administration accelerates the process.
Protein-calorie supplementation as one component of a comprehensive treatment
program may reverse the loss of muscle mass, and dietary counseling may aid patients at
high nutritional risk. Providing more fat-based nonprotein calories may benefit patients
with respiratory failure who are on mechanical ventilation, but, other than this special
circumstance, little evidence exists to suggest that this dietary manipulation aids
ambulatory patients.
Activity: Dyspnea limits activity, which results in deconditioning and further reductions in
activity levels. Encourage all patients with lung disease to maintain activity levels.
Pulmonary rehabilitation programs and patient support groups are particularly helpful.
MEDICATION Section 7 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Treat airflow obstruction and symptoms resulting from AAT deficiency in a manner similar
to emphysema. Bronchodilators may provide relief of some symptoms. Use antibiotics to
treat bacterial complications, including pneumonia or purulent bronchitis. Neither
bronchodilators nor antibiotics demonstrate any effect on disease progression. Similarly,
corticosteroids may provide some short-term relief but have no proven long-term benefit in
inhaled or oral preparations. Because of their long-term adverse effects, avoid oral
steroids. Prescribe oxygen if patients are hypoxemic. Consider replacement (or
augmentation) therapy to slow the progression of emphysema.
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Measuring pulmonary function yearly permits better counseling and planning for
interventions such as initiating replacement therapy (if not already started) or
transplantation preparation.
Transfer:
Complications:
Prognosis:
The major manifestation of AAT deficiency in the first 2 decades of life is liver
disease; pulmonary manifestations appear later. Lung function appears to be
normal among PiZZ adolescents when compared to a similar matched group with
alpha1 antiprotease levels within the reference range. FVC, FEV 1, residual volume,
and total lung capacity measurements were not different between the 2 groups.
Lung function begins to decline at some later point. FEV 1 decreases in adult PiZZ
patients at 51-317 mL per year (estimated decline in healthy patients is 30 mL/y).
o In the NIH registry, PiZZ individuals had a 16% chance of surviving to age 60
years in contrast to an 85% chance for the general US population.
Emphysema was the most common cause of death (72%), and chronic liver
disease was second (10%).
o In the Danish registry, the outlook was better, especially for nonindex cases
involving nonsmokers. In this group, survival closely approximated that of
the healthy Danish population. The Danish registry confirmed the poor
outlook for index cases and the additional mortality risk among smoking
patients.
o More severe degree of airflow obstruction (FEV 1 >50%, 5-y mortality rate is
4%; FEV1 35-49%, 5-y mortality rate is 12%; FEV1 <35, 5-y mortality rate is
50%)
o Smoking
o Male sex
Patient Education:
MISCELLANEOUS Section 9 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Medical/Legal Pitfalls:
Most patients with symptomatic AAT deficiency have seen several physicians over
several years before their underlying problem is recognized and diagnosed. A
patient could claim that (1) the physician failed to establish a diagnosis even though
diagnostic testing was readily available and inexpensive, (2) that appropriate
treatment was delayed, (3) that specific educational and counseling opportunities
were missed, and (4) that all of these harmed the patient.
Special Concerns:
Direct population screening studies in Sweden and the United States identified 1 in
3000-5000 whites with the PiZZ phenotype. These studies suggest that about
70,000-100,000 individuals in the United States may have severe AAT deficiency,
but fewer than 10,000 have been recognized, and fewer than 50% of these are
receiving replacement therapy. Most of the 10,000 patients (approximately 80%)
were identified because they were symptomatic; the remaining 20% are relatives of
index cases. If estimates are correct, an additional 60,000-90,000 AAT-deficient
individuals remain unidentified in the country. This suggests that physicians may be
missing cases and that some affected individuals may have not yet developed
significant disease. Evidence for both of these possibilities exists.
PICTURES
Section 10 of 11
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Caption: Picture 1. Close-up chest radiographic view of right lower zone of a 39-
year-old woman with alpha1-antitrypsin (AAT) deficiency. Normal lung markings are
absent in the costophrenic angle. Some lung markings are present in the pericardiac
region, but even these are diminished.
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography
Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies
daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate
and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and
human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not
warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results
of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug
doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER